Biohaven Pharmaceutical Holding Co Ltd.
biohaven.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q2 FY2022 10-Q, filed Aug 5, 2022. Its latest SEC filing is a 15-12G from Oct 14, 2022.
10-Q for Q2 FY2022, filed Aug 5, 2022
The sections below describe the company as of the FY2021 annual report.
What Did They Do?
Sells prescription migraine medicine to pharmaceutical wholesalers and develops drug candidates for patients with neurological and neuropsychiatric diseases.
10-K for FY2021, filed Feb 25, 2022
Who Were Their Customers?
Pharmaceutical wholesale distributors buy Biohaven's products and resell them to pharmacies and health care providers.
How Were They Changing?
- Net income
-
Sources
10-Q for Q2 FY2022, filed Aug 6, 2022
−$441.9MView ↗
- ▲ +109% (Loss)
- vs −$211.2M in Q2 FY2021
-
Oct 3, 2022
Pfizer completed its acquisition of Biohaven
Biohaven became a wholly owned subsidiary of Pfizer, and shareholders' shares converted to cash.
Sources
8-K, filed Oct 3, 2022
(i)Company Share that was issued and outstanding immediately prior to the Effective Time (other than (A) Company Shares owned by the…View ↗
Loading...
